Australia vs Oman: The number of people with susceptibility test result for rifampicin
Australia
83.5
in 2021
Oman
84.21
in 2021
Australia rank
90th
Oman rank
87th
The number of people with susceptibility test result for rifampicin over time
- Australia
- Oman
How they compare
Oman currently reports 84.21 against 83.5 in Australia, a difference of 0.71.
The two have swapped places 2 times across 5 shared years of data; in 2017 it was Oman ahead.
Australia ranks 90th and Oman ranks 87th of 146 countries.
Across the 2 decades both report, Australia averaged higher in 1 and Oman in 1.
Head to head by decade
| Decade | Australia | Oman | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 92.62 | 100 | 7.38 | Oman |
| 2020s | 88.8 | 87.9 | 0.8998 | Australia |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher the number of people with susceptibility test result for rifampicin, Australia or Oman?
- Oman, at 84.21 against 83.5 in Australia as of 2021.
- What is the difference in the number of people with susceptibility test result for rifampicin between Australia and Oman?
- 0.71, with Oman ahead.
- How many years of comparable data are there for Australia and Oman?
- 5 years are reported by both, from 2017 to 2021.
- How do Australia and Oman rank globally for the number of people with susceptibility test result for rifampicin?
- Australia ranks 90th and Oman ranks 87th of 146 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.. Statizoid refreshes it automatically from the source and publishes the full history for both places.